261023 – Melanoma mRNA Vaccine

October 23, 2026 Leave a comment

A Vaccine Built From Your Own Tumor: Reading the Melanoma mRNA Trial

ยท @Thomas Lee Abshier, ND

What was announced

On October 22, 2026, Merck and Moderna released the full Phase 3 results for intismeran autogene, a personalized mRNA treatment for melanoma, and the headlines said it cut the risk of recurrence or death “by almost half.” The trial, called INTerpath-001, enrolled 1,137 patients whose high-risk melanoma (stage IIB through IV) had already been surgically removed. Adding intismeran to the standard immunotherapy drug Keytruda (pembrolizumab) reduced the risk of recurrence or death by 42 percent and the risk of distant spread or death by 38 percent, compared with Keytruda plus a placebo.

The numbers leaked a day before their scheduled presentation at the European Society for Medical Oncology congress in Madrid on October 24, and Moderna’s stock fell by roughly a fifth to a quarter that day. Investors had expected a larger effect, based on an earlier and smaller Phase 2b trial. The results have been accepted for publication in The New England Journal of Medicine, and the companies say they are engaging with regulators.

My position is this: the result is real, the trial was well designed, and for patients facing a high chance of their melanoma returning, this is a genuine advance worth taking seriously. Read it in proportion. The headline figure is a relative reduction, the treatment is not a vaccine in the sense most readers assume, survival data are not yet mature, and the people telling the story have billions of dollars riding on how it is told.

What the treatment actually is

Intismeran is a treatment for people who already have cancer, not a shot that prevents cancer in healthy people. The word “vaccine” invites the wrong picture; the companies themselves call it an “individualized neoantigen therapy.”

It is made one patient at a time:

  1. The surgeon removes the tumor, and the lab sequences both the tumor’s DNA and the patient’s normal DNA.
  2. Comparing the two reveals mutations found only in the cancer. Some of these produce altered protein fragments, called neoantigens, that the immune system could in principle recognize as foreign.
  3. A computer selects up to 34 of the most promising neoantigens, and Moderna writes a single strand of synthetic mRNA that codes for all of them.
  4. The patient receives this mRNA by injection every three weeks for up to nine doses, alongside Keytruda, for about a year.

Once injected, the patient’s own cells read the mRNA and display the tumor fragments to the immune system, training T cells to hunt down any remaining cancer cells that carry those mutations. Keytruda, a PD-1 blocker, releases a brake that tumors use to switch T cells off. The two work as a pair: one shows the immune system the target, the other lets it fire.

The numbers in proportion

In absolute terms, about 12 more patients out of every 100 were alive and free of melanoma at two years with intismeran than without it. That is the figure a patient should weigh, and it is substantial. “Almost half” describes the relative risk reduction; the absolute numbers show how many people that actually spares.

At two years (median follow-up 24.6 months) Intismeran + Keytruda Placebo + Keytruda Difference
Alive with no recurrence 82.2% 70.0% 12.2 points
Recurred or died 17.8% 30.0% about 1 in 8 patients treated spared
Alive with no distant spread 88.5% 80.2% 8.3 points
Distant spread or died 11.5% 19.8% about 1 in 12 patients treated spared

Source: Merck/Moderna release of October 22, 2026. The “1 in 8” and “1 in 12” figures are my arithmetic (number needed to treat), not the companies’.

The design was strong. This was a randomized, double-blind trial with a placebo injection in the control arm, so neither patients nor doctors knew who received the real treatment. Both arms received the current standard of care, so the comparison asks the right question: does adding intismeran help beyond what patients would already receive?

The benefit appeared only after about six months. During the first six months, the two arms did equally well. After the nine-dose immunization course was complete, a pre-specified analysis showed a 58 percent reduction in recurrence or death. That delay fits the biology, since training T cells takes time, but it also means patients whose cancer returns early may gain nothing.

Some of the larger percentages come from narrower analyses. When the companies excluded patients who never received a dose of intismeran or placebo, the reduction rose to 49 percent. The 42 percent figure, which counts everyone as randomized, is the honest headline.

Survival is not yet known. Overall survival is “not yet mature”; the companies report only a favorable trend. In the earlier Phase 2b trial of 157 patients, five-year survival was 92.2 percent with the combination versus 71.3 percent with Keytruda alone, but that trial was small and open-label, and its survival analysis was exploratory with a confidence interval wide enough to include no benefit at all.

The effect is durable so far. The Phase 2b trial showed the recurrence benefit holding at five years: 68.8 percent recurrence-free versus 49.1 percent. Phase 3 now confirms that direction in a trial seven times larger, with a somewhat smaller effect, which is typical when a promising early finding is tested at scale.

Safety, and the mRNA question

Adding intismeran made common side effects more frequent but did not measurably raise serious ones. Serious (grade 3 to 5) treatment-related events occurred in 14.2 percent of the intismeran group and 13.4 percent of the Keytruda-alone group. Most of the serious harm in both arms comes from Keytruda, which can provoke immune attack on the thyroid, colon, lungs, liver, and other organs.

What intismeran added was mostly a strong immune reaction: fever in 52 percent, injection-site pain in 51 percent, and fatigue in 38.5 percent. In the five-year Phase 2b follow-up, no new late-onset toxicities were reported, though 157 patients is too few to detect rare events.

Many readers of this site came to mRNA technology through the COVID vaccines, and some hold well-founded concerns from that experience, including the documented myocarditis risk in young men. Those concerns deserve a direct answer here, and the answer is that the two situations differ in every way that governs a risk-benefit judgment:

  • Who receives it. The COVID shots were given to hundreds of millions of mostly healthy people, many at very low risk from the disease. Intismeran is given to people who have already had a dangerous cancer and face roughly a 30 percent chance of recurrence or death within two years even on standard treatment.
  • What the mRNA codes for. The COVID vaccines code for the viral spike protein, which itself has biological activity. Intismeran codes for short fragments of the patient’s own mutated tumor proteins, chosen precisely because they exist nowhere else in the body.
  • How the decision is made. Intismeran would be a prescribed cancer treatment chosen by an informed patient with his oncologist, not a mass campaign accompanied by mandates and public pressure.

The general questions raised during the pandemic, such as how far the lipid nanoparticle carrier travels in the body and how long the mRNA persists, apply in principle to this product too. They should be studied and reported. But a patient with resected stage III melanoma is weighing them against a far larger and nearer threat.

What remains open

Five questions should be settled before anyone calls this a cure.

  1. Peer review. Everything public so far comes from the sponsors’ press release. The full paper in The New England Journal of Medicine will show the subgroups, the dropouts, and why some randomized patients never received a single dose.
  2. Survival. Fewer recurrences usually mean longer lives, but not always; some recurrences are caught early and treated successfully. Only mature overall survival data can show whether patients actually live longer.
  3. Comparison with other approaches. Analysts at RBC Capital Markets questioned whether intismeran adds enough value over neoadjuvant immunotherapy, meaning immunotherapy given before surgery, which may deliver similar benefit at lower cost. INTerpath-001 did not test that comparison.
  4. Cost and access. A drug made separately for each patient, from sequencing to synthesis, will be expensive. No price has been announced. A treatment available only at major academic centers helps fewer people than the trial numbers suggest.
  5. Other cancers. Melanoma is unusually rich in mutations, largely from sun damage, which gives the immune system many targets. Cancers with fewer mutations may respond less. This month, BioNTech reported that its mRNA cancer vaccine for head and neck cancer missed one of its survival goals, reminding us that one success does not make a platform.

The FDA also has never ruled on a product like this. As Karen Knudsen of the Parker Institute told The Washington Post, it will be new territory for the agency.

The physiological lesson

The most important thing this trial teaches is not about mRNA. The body’s immune system can recognize and control cancer when it sees the right targets and is free to act.

Immunologists call this immune surveillance: T cells patrol the body and destroy cells that display abnormal proteins. Cancer survives by hiding its abnormal proteins or by switching off patrolling T cells. Intismeran addresses the first problem and Keytruda the second. In the Phase 2b trial, patients who stayed free of cancer had roughly twice as many newly expanded T-cell families as those whose cancer returned, which suggests the treatment works by building new immune memory rather than by poisoning the tumor.

This is a principle naturopathic medicine has long honored: nature’s healing power, the body’s capacity to restore order, is the primary physician, and the practitioner’s task is to remove obstacles and support it. Here, the most advanced tools in molecular medicine do exactly that. That convergence deserves attention, but it does not license the opposite error. No diet, supplement, or herb has been shown in a controlled trial to produce the kind of targeted T-cell response measured here, and none should be presented as a substitute for it.

For readers without melanoma, the practical lessons are the old ones, and they still matter most:

  • Avoid sunburn, especially in children; a history of blistering burns is among the strongest known risk factors. Regular, moderate sun exposure without burning differs from intermittent intense exposure.
  • Know your skin. Check it monthly for a mole that is asymmetric, has an irregular border, uneven color, a diameter larger than a pencil eraser, or is changing.
  • Have suspicious spots examined promptly. Melanoma removed while thin is usually cured by surgery alone; the patients in this trial were those whose disease had already gone deeper.
  • If you have had melanoma removed, ask your oncologist about your stage, your recurrence risk, and whether a trial of this kind is open to you.

Where I stand

I stand on the side of this treatment as a genuine advance for patients with high-risk melanoma after surgery. A double-blind, placebo-controlled trial of more than a thousand patients found that about one in eight treated patients avoided recurrence or death over two years, with no measurable increase in serious side effects beyond those of the standard drug. A properly informed patient in that situation has good reason to want it.

The areas of uncertainty are real and specific: survival data are immature, the full paper is not yet public, the comparison with pre-surgical immunotherapy is untested, the price is unknown, and success in melanoma does not predict success in other cancers.

A skeptical reader’s caution about how this story is told also remains well founded, for three reasons:

  • The money is enormous, and it shapes the language. Moderna’s share price moved by a fifth in a day on this trial. Executives speaking of a “defining moment” and “curative potential” are speaking partly to investors. The word “vaccine” borrows public familiarity from the COVID campaign, and the phrase “almost half” borrows the force of a relative number.
  • The platform is being sold along with the product. Statements that mRNA could “fundamentally change how we treat cancer” ask the public to extend trust from one well-designed melanoma trial to a whole technology. That trust should be earned trial by trial, cancer by cancer.
  • Institutions have earned the scrutiny. After the COVID years, when mRNA products were promoted to low-risk groups with little room for dissent, many people lost confidence in how drug makers and regulators communicate risk. That loss is not cured by one good result; it is cured by consistent candor, including candor about absolute numbers and about what is still unknown.

The right response to this news is neither the enthusiasm of the press releases nor reflexive rejection because the letters “mRNA” appear. It is to ask, as we should of every treatment: for whom, by how much, at what cost, and compared with what. For this patient group, the answers so far are encouraging.

Sources

Leave a Reply

Your email address will not be published. Required fields are marked *